Originally published as JCO Early Release 10.1200/JCO.2007.11.9214 on April 14 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sloand, E. M. Articles by Barrett, J. Search for Related Content PubMed PubMed Citation Articles by Sloand, E. M. Articles by Barrett, J. Social Bookmarking                            What's this?

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

Elaine M. Sloand, Colin O. Wu, Peter Greenberg, Neal Young, John Barrett

From the National Heart, Lung and Blood Institute, Division of Intramural Research, Hematology Branch, Bethesda, MD; and Hematology Division, Stanford University Cancer Center, Stanford, CA

Corresponding author: Elaine M. Sloand, National Heart, Lung and Blood Institute, 9000 Rockville Pike, Bldg 10, CRC 5230, Bethesda, MD 20892; e-mail: sloande{at}nhlbi.nih.gov

Purpose Marrow failure in some patients with myelodysplastic syndrome (MDS) responds to immunosuppressive treatment (IST), but long-term outcome after IST has not been described. We evaluated patients with MDS treated with IST at our institution to determine their clinical course compared with a comparable supportive care only group.

Patients and Methods One hundred twenty-nine patients with MDS received IST with a median follow-up of 3.0 years (range, 0.03 to 11.3 years), using antithymocyte globulin (ATG) or cyclosporine (CsA) in combination or singly. Variables affecting response and survival were studied and outcomes were compared with those of 816 patients with MDS reported to the International Myelodysplasia Risk Analysis Workshop (IMRAW) who received only supportive care.

Results Thirty-nine (30%) of 129 patients receiving IST responded either completely or partially: 18 (24%) of 74 patients responded to ATG, 20 (48%) of 42 patients responded to ATG plus CsA, and one (8%) of 13 patients responded to CsA. Thirty-one percent (12 of 39) of the responses were complete, resulting in transfusion independence and near-normal blood counts. In multivariate analysis, younger age was the most significant factor favoring response to therapy. Other favorable factors affecting response were HLA-DR15 positivity and combination ATG plus CsA treatment (P = .001 and P = .048, respectively). In multivariate analysis of the combined IMRAW and IST cohorts, younger age, treatment with IST, and intermediate or low International Prognostic Scoring System score significantly favored survival.

Conclusion IST produced significant improvement in the pancytopenia of a substantial proportion of patients with MDS and was associated with improved overall and progression-free survival, especially in younger individuals with lower-risk disease.

published online ahead of print at www.jco.org on April 14, 2008

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J. Barrett and E. Sloand Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance Haematologica, April 1, 2009; 94(4): 449 - 451. [Full Text] [PDF]

				M. E.D. Chamuleau, T. M. Westers, L. van Dreunen, J. Groenland, A. Zevenbergen, C. M. Eeltink, G. J. Ossenkoppele, and A. A. van de Loosdrecht Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome Haematologica, April 1, 2009; 94(4): 496 - 506. [Abstract] [Full Text] [PDF]

				J. M. Bennett and A. Orazi Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach Haematologica, February 1, 2009; 94(2): 264 - 268. [Abstract] [Full Text] [PDF]

				N. S. Young Paroxysmal nocturnal hemoglobinuria and myelodysplastic sydromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure Haematologica, January 1, 2009; 94(1): 3 - 7. [Full Text] [PDF]

				G. Garcia-Manero Standard-of-care Approaches for Myelodysplastic Syndromes ASCO Educational Book, January 1, 2009; 2009(1): 408 - 412. [Abstract] [Full Text] [PDF]